Endo, a wholly-owned subsidiary of American-Irish pharmaceutical company Mallinckrodt plc, announced on Wednesday that two presentations related to plantar fibromatosis (PFI) and plantar fasciitis (PFA) will be shared during the American Orthopaedic Foot & Ankle Society Annual Meeting, taking place from 10-13 September 2025.

The presentations cover findings from Phase 1 and Phase 2 studies of collagenase clostridium histolyticum (CCH) in patients with PFA and PFI, respectively.

The two Endo-supported presentations are:

* Collagenase Clostridium Histolyticum (CCH) in Patients With Plantar Fibromatosis (PFI): Post Hoc Analysis of a Phase 2, Double-blind, Randomised, Placebo-Controlled Study

Authors: Saadiq El-Amin, MD, PhD; C. James Anderson, DPM; Ira Gottlieb DPM; Jason Levy, DPM, FACFAS; Sara E. Suttle, DPM, FACFAS; James Tursi, MD; Nigel Jones, PharmD; Luis Ortega, MD; Gongfu Zhou, PhD; Joseph Caporusso, DPM.

* A Phase 1, Single-Blind, Randomized, Placebo-Controlled Dose Escalation Study to Assess Collagenase Clostridium Histolyticum (CCH) vs Placebo in Patients With Plantar Fasciitis (PFA)

Authors: Saadiq El-Amin, MD, PhD; Joseph Caporusso, DPM; Ira Gottlieb, DPM; Jason Levy, DPM, FACFAS; Sara Suttle, DPM, FACFAS; James Tursi, MD; Nigel Jones, PharmD; Luis Ortega, MD; Jeffrey Andrews, MS; C. James Anderson, DPM.

CCH is not approved for use in treating patients with PFI or PFA. Endo is currently enrolling patients in the pivotal Phase 3 program for PFI.